Coherus Oncology
As of the edition of 20 October 2026, Coherus Oncology runs 8 drugs, 1 of them marketed; it is on route A at 2 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Surface Oncology: acquired in 2023; successor Coherus BioSciences, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 5 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Toripalimab | Ends 2035 (computed from the first US licence) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 1 target.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Coherus Oncology needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 10 trials led
- Digestive system: 5 trials led
- Lungs and airways: 2 trials led